MabThera 10 years of clinical experience – Laying foundations for the future
April 21, 2010
| Abstract Title: | MabThera 10 years of clinical experience – Laying foundations for the future |
| Authors: | Hortensia Ionita |
| Affiliation: | University of Medicine and Pharmacy „Victor Babes”, Timisoara, Romania |
| Abstract text: | Rituximab is a monoclonal antibody widely and successfully used for the treatment of the most frequent hematological malignancies: FL, DLBCL, and CLL both in first line and relapsed/ refractory disease therapy setting. Rituximab-based induction and maintenance therapy has changed the course of FL. Rituximab plus chemotherapy increases survival and the chance of cure for patients with DLBCL. Rituximab plus chemotherapy prolongs remission for patients with first-line and relapsed CLL. Patient outcomes have improved over the last 10 years due to rituximab. Even after ten years of use rituximab-based therapy may be further optimised due to new combinations that emerge in the continuous search for improved patient outcomes in FL, DLBCL and CLL. Rituximab has changed the standard of care in NHL and CLL. |
| Keywords: | MabThera, clinical experience |
| Presentation type: | Oral |
| Correspondence: | |
| Email: | alcionasasu@yahoo.com |
About The Author
